Understanding drivers of the Black:White breast cancer mortality gap: A call for more robust definitions.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 35578909.
- Also identified by DOI 10.1002/cncr.34243 and PMC identifier 9325488.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Kim et al completed a pooled analysis of 8 National Surgical Adjuvant Breast and Bowel Project trials and highlight that, when compared with White patients, Black patients with estrogen receptor–positive (ER+) breast cancer have worse distant recurrence‐free survival, especially in the setting of neoadjuvant chemotherapy when pathologic complete response is not achieved. This editorial highlights that, to comprehend the drivers of this disparity, we must have more robust definitions of ER+ breast cancer and race.
Medical subject headings
- Breast Neoplasms